中医药防治慢性乙型肝炎肝纤维化的现状、挑战与思考

施梅姐; 萧焕明; 谢玉宝; 黎胜; 曾佛来; 池晓玲

doi:10.3969/j.issn.1001-5256.2023.06.004

中医药防治慢性乙型肝炎肝纤维化的现状、挑战与思考

DOI: 10.3969/j.issn.1001-5256.2023.06.004

广州中医药大学第二附属医院，广东省中医院肝病科，广州 510120

基金项目:

国家“十三五”重大传染病专项课题 (2018ZX10725506-003);

国家“十三五”重大传染病专项课题 (2018ZX10725505-004);

广东省基础与应用基础研究基金项目 (2022A1515110825);

广东省中医药局面上项目 (20211189);

广东省中医药局面上项目 (20225022);

广东省中医药局面上项目 (20231116);

广东省中医院院内专项 (YN10101903);

广东省中医院院内专项 (YN2016XP03);

广东省中医院院内专项 (YN2022DB04);

池晓玲国家中医药管理局名老中医药专家传承工作室项目 (Guozhong Pharmaceutical Human Education Letter [2022]No.75);

第五批全国中医临床优秀人才研修项目 (Guozhong Pharmaceutical Human Education Letter 2022]No.1)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：施梅姐撰写论文；萧焕明、谢玉宝、黎胜、曾佛来协助查阅文献; 池晓玲提供撰写思路，修改写作框架及审稿。

详细信息

通信作者:
池晓玲，chixiaolingqh@163.com (ORCID：0000-0003-3193-1943)

计量
- 文章访问数: 462
- HTML全文浏览量: 64
- PDF下载量: 90
- 被引次数: 0
出版历程
- 收稿日期: 2023-04-01
- 录用日期: 2023-05-01
- 出版日期: 2023-06-20

Role of traditional Chinese Medicine in prevention and treatment of chronic hepatitis B liver fibrosis: Current status, challenges, and thoughts

Department of Hepatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Research funding:

The Thirteenth Five Year Plan for Major and Special Programs of the National Science and Technology of China (2018ZX10725506-003);

The Thirteenth Five Year Plan for Major and Special Programs of the National Science and Technology of China (2018ZX10725505-004);

Guangdong Basic and Applied Basic Research Fund Project (2022A1515110825);

The General Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20211189);

The General Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20225022);

The General Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20231116);

The Science and Technology Research Project of Traditional Chinese Medicine of Guangdong Provincial Hospital of Chinese Medicine (YN10101903);

The Science and Technology Research Project of Traditional Chinese Medicine of Guangdong Provincial Hospital of Chinese Medicine (YN2016XP03);

The Science and Technology Research Project of Traditional Chinese Medicine of Guangdong Provincial Hospital of Chinese Medicine (YN2022DB04);

Chi Xiaoling of Project of Inheritance Workshop of Famous Old Chinese Medicine Experts of State Administration of Traditional Chinese Medicine (Guozhong Pharmaceutical Human Education Letter [2022]No.75);

The Fifth Batch of National Research and Training Programs for Clinical Talents of traditional Chinese Medicine (Guozhong Pharmaceutical Human Education Letter 2022]No.1)

More Information

Corresponding author: CHI Xiaoling, chixiaolingqh@163.com (ORCID: 0000-0003-3193-1943)

摘要

摘要: 近年来，中医药防治慢性乙型肝炎肝纤维化的相关研究取得了重大突破。在临床研究方面，产生了数个多中心的随机双盲对照研究，并以肝病理学变化为主要疗效评价指标，提高了中医药防治肝纤维化临床研究的证据级别。在基础研究方面，主要围绕影响肝星状细胞活化、凋亡与自噬、抑制肝脏炎症损伤、调节免疫、抑制肝窦毛细血管化等多个层面，深入研究了中医药抗肝纤维化的作用机制，突出了中医药“多成分、多靶点、多通路”的作用优势与研究难点。在《中医药振兴发展重大工程实施方案》的指引下，未来如何做更高质量的中医药抗肝纤维化的临床与基础研究，产出更高质量的行业成果，助力中医药抗肝纤维化走向世界是关键。
- 乙型肝炎, 慢性 /
- 肝纤维化 /
- 抗肝纤维化药(中药)
Abstract: In recent years, significant breakthroughs have been made in the research on the role of traditional Chinese medicine (TCM) in the prevention and treatment of chronic hepatitis B liver fibrosis. In terms of clinical research, several multicenter randomized double-blind controlled studies have been conducted with liver pathological changes as the main efficacy evaluation indicator, which have improved the level of evidence in clinical research on the TCM prevention and treatment of liver fibrosis. As for basic research, in-depth studies have been conducted on the mechanism of action of TCM in intervening against liver fibrosis at various levels, including the effect on HSC activation, apoptosis and autophagy, inhibition of liver inflammatory injury, immunoregulation, and inhibition of hepatic sinusoidal capillarization, thereby highlighting the advantages and research difficulties of TCM through "multiple components, targets, and pathways". Under the guidance of Implementation Plan for the Major Projects of Revitalizing and Developing TCM, it is crucial to conduct high-quality clinical and basic research on TCM in the treatment of liver fibrosis, produce high-quality industry achievements, and thus help TCM to be recognized around the world.
- Hepatitis B, Chronic /
- Hepatic Fibrosis /
- Anti-Hepato Fibrosis Agents (TCM)

HTML全文

参考文献(37)

[1]	SORIANO V, ALVAREZ C, EDAGWA B, et al. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis[J]. Int J Infect Dis, 2022, 114: 45-50. DOI: 10.1016/j.ijid.2021.10.052.
[2]	LIU YQ, ZHANG C, LI JW, et al. An-Luo-Hua-Xian Pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Clin Transl Hepatol, 2023, 11(2): 304-313. DOI: 10.14218/JCTH.2022.00091.
[3]	RONG G, CHEN Y, YU Z, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225(6): 1091-1099. DOI: 10.1093/infdis/jiaa266.
[4]	JI D, CHEN Y, BI J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77(6): 1515-1524. DOI: 10.1016/j.jhep.2022.07.018.
[5]	CHENG DY, ZHAO ZM, WAN G, et al. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(5): 479-484. DOI: 10.1016/j.hbpd.2022.03.007.
[6]	XIAO HM, SHI MJ, JIANG JM, et al. Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial[J]. J Ethnopharmacol, 2022, 293: 115210. DOI: 10.1016/j.jep.2022.115210.
[7]	Chinese Society of Traditional Chinese Medicine Hepatobiliary Diseases. Expert consensus on the clinical application of Biejia Jianwan in the treatment of liver fibrosis[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(6): 577-578, 584. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXGB202006031.htm 中华中医药学会肝胆病学分会. 鳖甲煎丸治疗肝纤维化临床应用专家共识[J]. 中西医结合肝病杂志, 2020, 30(6): 577-578, 584. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXGB202006031.htm
[8]	Chinese Society of Traditional Chinese Medicine Hepatobiliary Diseases. Expert consensus on the clinical application of Ganshuang Granules in the treatment of liver fibrosis[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(5): 481-482. DOI: 10.3969/j.issn.1005-0264.2020.05.033. 中华中医药学会肝胆病分会. 肝爽颗粒治疗肝纤维化临床应用专家共识[J]. 中西医结合肝病杂志, 2020, 30(5): 481-482. DOI: 10.3969/j.issn.1005-0264.2020.05.033.
[9]	WANG T, JIN W, HUANG Q, et al. Clinical efficacy and safety of eight traditional chinese medicine combined with entecavir in the treatment of chronic hepatitis B liver fibrosis in adults: A network meta-analysis[J]. Evid Based Complement Alternat Med, 2020, 2020: 7603410. DOI: 10.1155/2020/7603410.
[10]	YE F, XUE BY, WU MH, et al. Study on treating chronic hepatitis and hepatic fibrosis by eliminating damp -heat toxin and blood stasis[J]. Chin Arch Tradit Chin Med, 2007, 25(12): 2477-2480. DOI: 10.3969/j.issn.1673-7717.2007.12.020. 叶放, 薛博瑜, 吴勉华, 等. 重视对慢性肝炎肝纤维化进程中湿热瘀毒证治研究[J]. 中华中医药学刊, 2007, 25(12): 2477-2480. DOI: 10.3969/j.issn.1673-7717.2007.12.020.
[11]	LIN SN, HUANG B, ZHU YP, et al. Clinical observation on treating fibrosis of liver due to chronic virus B hepatitis with Zhuanggan Zhuyujian[J]. Chin J Integr Trad West Med Dig, 2010, 18(4): 230-232. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201004005.htm 林寿宁, 黄彬, 朱永苹, 等. 壮肝逐瘀煎治疗慢性乙型肝炎肝纤维化临床观察[J]. 中国中西医结合消化杂志, 2010, 18(4): 230-232. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201004005.htm
[12]	WANG JY, ZHANG MZ. Controlled clinical studies on liver fibrosis due to hepatitis B by treatment of tonifying kidney and softening liver[J]. J Liaoning Univ Tradit Chin Med, 2014, 16(6): 118-120. DOI: 10.13194/j.issn.1673-842x.2014.06.043. 王见义, 张美珠. 补肾柔肝方治疗乙肝后肝纤维化临床对照研究[J]. 辽宁中医药大学学报, 2014, 16(6): 118-120. DOI: 10.13194/j.issn.1673-842x.2014.06.043.
[13]	ZHU YL, CHI XL. Therapeutic effects of Heheshuyang recipe combined with entecavir on patients with chronic hepatitis B[J]. Guangxi Med J, 2015, 37(3): 321-323. DOI: 10.11675/j.issn.0253-4304.2015.03.11. 朱娅莉, 池晓玲. 和合疏养方联合恩替卡韦治疗慢性乙型肝炎临床疗效观察[J]. 广西医学, 2015, 37(3): 321-323. DOI: 10.11675/j.issn.0253-4304.2015.03.11.
[14]	ZHUO YX, PENG MN, LIN M, et al. Evaluation of clinical effect of therapy of soothing liver and invigorating spleen for treatment of hepatitis B associated hepatic fibrosis[J]. J Guangzhou Univ Tradit Chin Med, 2020, 37(11): 2063-2068. DOI: 10.13359/j.cnki.gzxbtcm.2020.11.003. 卓永祥, 彭梦楠, 林明, 等. 运用疏肝健脾法治疗乙肝肝纤维化的临床疗效评价[J]. 广州中医药大学学报, 2020, 37(11): 2063-2068. DOI: 10.13359/j.cnki.gzxbtcm.2020.11.003.
[15]	WANG L, LU W, GAO YH, et al. Effect of Anluohuaxianwan on the expression of matrix metalloproteinases and their inhibitors in rat liver with fibrosis[J]. Chin J Hepatol, 2019, 27(4): 267-273. DOI: 10.3760/cma.j.issn.l007-3418.2019.04.006. 王林, 卢玮, 高玉华, 等. 安络化纤丸对肝纤维化大鼠肝组织基质金属蛋白酶及其抑制物表达的影响[J]. 中华肝脏病杂志, 2019, 27(4): 267-273. DOI: 10.3760/cma.j.issn.l007-3418.2019.04.006.
[16]	SHEN B, DENG L, LIU Y, et al. Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl₄-induced liver fibrosis[J]. Chin Herb Med, 2022, 14(1): 104-110. DOI: 10.1016/j.chmed.2021.09.013.
[17]	DONG BS, LIU FQ, YANG WN, et al. Huangqi Decoction, a compound Chinese herbal medicine, inhibits the proliferation and activation of hepatic stellate cells by regulating the long noncoding RNA-C18orf26-1/microRNA-663a/transforming growth factor-β axis[J]. J Integr Med, 2023, 21(1): 47-61. DOI: 10.1016/j.joim.2022.11.002.
[18]	ZHANG Y, HUA L, LIN C, et al. Pien-Tze-Huang alleviates CCl₄-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway[J]. Front Pharmacol, 2022, 13: 937484. DOI: 10.3389/fphar.2022.937484.
[19]	ZHENG Y, ZHAO T, WANG J, et al. Curcumol alleviates liver fibrosis through inducing autophagy and ferroptosis in hepatic stellate cells[J]. FASEB J, 2022, 36(12): e22665. DOI: 10.1096/fj.202200933RR.
[20]	CHEN CH, CHEN MF, HUANG SJ, et al. Saikosaponin a induces apoptosis through mitochondria-dependent pathway in hepatic stellate cells[J]. Am J Chin Med, 2017, 45(2): 351-368. DOI: 10.1142/S0192415X17500227.
[21]	MA C, WANG C, ZHANG Y, et al. Phillygenin inhibited M1 macrophage polarization and reduced hepatic stellate cell activation by inhibiting macrophage exosomal miR-125b-5p[J]. Biomed Pharmacother, 2023, 159: 114264. DOI: 10.1016/j.biopha.2023.114264.
[22]	WANG SW, LAN T, ZHENG F, et al. Effect of extract of Quzhou Aurantii Fructus on hepatic inflammation and NF-κB/NLRP3 inflammasome pathway in CCl₄-induced liver fibrosis mice[J]. China J Chin Mater Med, 2021, 46(6): 1474-1479. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY202106021.htm 王思为, 蓝天, 郑芳, 等. 衢枳壳提取物对CCl₄诱导的肝纤维化小鼠肝脏炎症及NF-κB/NLRP3炎性体通路的影响[J]. 中国中药杂志, 2021, 46(6): 1474-1479. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY202106021.htm
[23]	XU J, ZHONG ML, WANG YF, et al. Study on intervention of DCP on MAPK signaling pathway to inhibit inflammatory response and alleviate progression of liver fibrosis in rats[J]. Chin Pharmacol Bull, 2022, 38(4): 531-537. DOI: 10.12360/CPB202106059. 徐杰, 钟明利, 王跃峰, 等. 狗肝菜多糖干预MAPK信号通路抑制炎症反应缓解大鼠肝纤维化进程[J]. 中国药理学通报, 2022, 38(4): 531-537. DOI: 10.12360/CPB202106059.
[24]	CHANG QQ, PAN YF, YANG JY, et al. Antiliver fibrosis formula of fuzheng huayu alleviates inflammatory response[J]. Evid Based Complement Alternat Med, 2022, 2022: 5752803. DOI: 10.1155/2022/5752803.
[25]	JIANG C, IWAISAKO K, CONG M, et al. Traditional Chinese Medicine Fuzheng Huayu prevents development of liver fibrosis in mice[J]. Arch Clin Biomed Res, 2020, 4(5): 561-580. DOI: 10.26502/acbr.50170125.
[26]	GUO XH, ZHENG Y, WANG JH, et al. Research progress on the role of traditional Chinese medicine in the occurrence of liver fibrosis based on miRNA mediated activation of NLRP3 inflammasomes[J]. China J Chin Mater Med, 2022, 47(9): 2409-2418. DOI: 10.19540/j.cnki.cjcmm.20211009.401. 郭新华, 郑洋, 王佳慧, 等. 基于miRNA介导的NLRP3炎症小体活化探讨中医药在肝纤维化发生中作用的研究进展[J]. 中国中药杂志, 2022, 47(9): 2409-2418. DOI: 10.19540/j.cnki.cjcmm.20211009.401.
[27]	MO C, XIE SW, GAO L, et al. Baoganning formula alleviates liver fibrosis in mice by inhibiting hepatic IDO1 expression and promoting phenotypic maturation of dendritic cells[J]. J South Med Univ, 2021, 41(7): 1002-1011. DOI: 10.12122/j.issn.1673-4254.2021.07.06. 莫婵, 谢淑雯, 高磊, 等. 复方保肝宁减轻小鼠肝纤维化的机制: 抑制肝脏组织中的IDO1进而促进树突状细胞表型成熟[J]. 南方医科大学学报, 2021, 41(7): 1002-1011. DOI: 10.12122/j.issn.1673-4254.2021.07.06.
[28]	PENG Y, YANG T, HUANG K, et al. Salvia miltiorrhiza ameliorates liver fibrosis by activating hepatic natural killer cells in vivo and in vitro[J]. Front Pharmacol, 2018, 9: 762. DOI: 10.3389/fphar.2018.00762.
[29]	LIU YT, LV WL. Research progress in astragalus membranaceus and its active components on immune responses in liver fibrosis[J]. Chin J Integr Med, 2020, 26(10): 794-800. DOI: 10.1007/s11655-019-3039-1.
[30]	CHEN L, XIA S, WANG S, et al. Naringenin is a potential immunomodulator for inhibiting liver fibrosis by inhibiting the cGAS-STING pathway[J]. J Clin Transl Hepatol, 2023, 11(1): 26-37. DOI: 10.14218/JCTH.2022.00120.
[31]	WU HJ, WU SD, CHI XL, et al. Regulating effect of hehe shuyang tang on immunologic function of chronic hepatitis B patients with liver-stagnation and spleen-deficiency syndrome[J]. J New Chin Med, 2016, 48(5): 99-102. DOI: 10.13457/j.cnki.jncm.2016.05.038. 吴惠君, 吴树铎, 池晓玲, 等. 和合疏养方对肝郁脾虚证慢性乙型肝炎患者免疫功能的调节作用[J]. 新中医, 2016, 48(5): 99-102. DOI: 10.13457/j.cnki.jncm.2016.05.038.
[32]	WU Y, LI Z, XIU AY, et al. Carvedilol attenuates carbon tetrachloride-induced liver fibrosis and hepatic sinusoidal capillarization in mice[J]. Drug Des Devel Ther, 2019, 13: 2667-2676. DOI: 10.2147/DDDT.S210797.
[33]	LIU P. Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis[J]. Chin J Integr Med, 2016, 22(8): 569-572. DOI: 10.1007/s11655-016-2468-3.
[34]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[35]	ZHANG LJ, SUN MY, NING BB, et al. Xiayuxue Decoction ([symbols; see text]) attenuates hepatic stellate cell activation and sinusoidal endothelium defenestration in CCl4-induced fibrotic liver of mice[J]. Chin J Integr Med, 2014, 20(7): 516-523. DOI: 10.1007/s11655-014-1862-y.
[36]	LU J, ZHOU N, HUANG Y, et al. Effects of Shugan Jianpi Huoxue Decoctionon expression of VEGF/VEGFR in hepatic stellate cells liver sinusoidal endothelial cell co-culture system[J]. J Tradit Chin Med, 2019, 60(3): 242-247. DOI: 10.13288/j.11-2166/r.2019.03.015. 鲁军, 周凝, 黄棪, 等. 疏肝健脾活血方对肝星状细胞/肝窦内皮细胞共培养体系中VEGF/VEGFR表达的影响[J]. 中医杂志, 2019, 60(3): 242-247. DOI: 10.13288/j.11-2166/r.2019.03.015.
[37]	GAO L, YANG X, LI Y, et al. Curcumol inhibits KLF5-dependent angiogenesis by blocking the ROS/ERK signaling in liver sinusoidal endothelial cells[J]. Life Sci, 2021, 264: 118696. DOI: 10.1016/j.lfs.2020.118696.